Stanley C. Erck - 14 Dec 2021 Form 4 Insider Report for NOVAVAX INC (NVAX)

Role: President and CEO, Director
Signature: /s/ John A. Herrmann III, Attorney-in-Fact
Issuer symbol: NVAX
Transactions as of: 14 Dec 2021
Net transactions value: -$566,935
Form type: 4
Filing time: 16 Dec 2021, 16:14:30 UTC
Previous filing: 05 Oct 2021
Next filing: 14 Mar 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	NVAX	Common Stock	Options Exercise		+6,967	+29%		30,846	14 Dec 2021	Direct	F1
transaction	NVAX	Common Stock	Tax liability	$566,935	-3,366	-11%	$168.43^*	27,480	14 Dec 2021	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	NVAX	Restricted Stock Units	Options Exercise	$0	-6,967	-33%	$0.000000	13,933	14 Dec 2021	Common Stock	6,967		Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each restricted stock unit ("RSU") represents a contingent right to receive one share of Novavax, Inc. (the "Company") common stock.
F2	The RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, vested or will vest with respect to one-third (1/3) of the RSUs on each of the first three (3) anniversaries of the December 14, 2020 grant date, in each case subject to continued employment through such vesting date.